Ultra-LEAF™ Purified anti-mouse CD30 Antibody, CD30, A23078B,BioLegend,667354

CD30, also known as TNFRSF8, is a member of the tumor necrosis factor (TNF) receptor superfamily and was originally identified as a cell surface antigen Ki-1, on Hodgkin and Reed-Sternberg cells. CD30 can be cleaved by cell membrane-anchored metalloproteinases and then released from the cell as a soluble form protein. CD30 is expressed on activated T, B, and NK cells, but not on resting T, and B cells. CD30 is also highly expressed in, among others, classical Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). CD30 interacts with a number of proteins including TRAF1, TRAF2, TRAF3, TRAF5, NPM-ALK, TRAF-interacting protein, and CD30 ligand (CD153). Signaling through CD30 is thought to limit the proliferative potential of autoreactive CD8 effector T cells and protect against autoimmunity. CD30 mediates the signal transduction that leads to the activation of the nuclear factor kappaB (NF-kB) transcription factor. Coexpression of CD30 with TRAF1 augments NF-kB activation. In addition, CD30 also has been identified as a critical therapeutic target for lymphoma immunotherapy. CD30L/CD30 signaling has been implicated in the pathogenesis of several autoimmune and inflammatory conditions, such as rheumatoid arthritis (RA). Furthermore, CD30L/CD30 signaling appears to be involved in Th1 and Th2 cell responses and plays a key role in Th17 differentiation in mice.